1-(sulfamoylamino)propane | CAS:147962-41-2

We serve 1-(sulfamoylamino)propane CAS:147962-41-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-(sulfamoylamino)propane

Chemical Name:1-(sulfamoylamino)propane
CAS.NO:147962-41-2
Synonyms:1-(sulfamoylamino)propane
Sulfamide,propyl
N-propylsulfamide
Propylsulfamide
N-Propylsulfuric diamide
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 249.0±23.0 °C at 760 mmHg
Molecular Formula C3H10N2O2S
Molecular Weight 138.189
Flash Point 104.4±22.6 °C
 
Specification:
Appearance:White to off-white lumps
Assay:≥99.0%
Moisture:≤5.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Macitentan(CAS:441798-33-0).



Contact us for information like 1-(sulfamoylamino)propane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Propylsulfuric diamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Propylsulfamide Use and application,1-(sulfamoylamino)propane technical grade,usp/ep/jp grade.


Related News: The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine manufacturer f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.β-(4-CHLOROPHENYL)GLUTARIC ANHYDRIDE supplier f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.3-bromo-1-phenyl-5-pyridin-2-ylpyridin-2-one vendor Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.